FIELD: medicine.
SUBSTANCE: group of inventions relates to treatment of movement disorders. Application of composition is proposed, which contains zolmitriptan or its pharmaceutically acceptable salt and 5-HT-receptor agonist buspirone or its pharmaceutically acceptable salt for treating, preventing or relieving movement disorders and use of set containing pharmaceutical composition of zolmitriptan or its salt and pharmaceutical composition of 5-HT-receptor agonist buspirone or its salt, at same prescription.
EFFECT: technical result is increased efficiency of combined treatment in part of manifestations of delayed dyskinesia and relief of symptoms of Parkinson's disease in its model in rats.
13 cl, 4 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL PHARMACEUTICAL COMPOSITION SUITABLE FOR IMPROVING EFFECTIVENESS OF TREATMENT OF MOTOR DISORDERS | 2013 |
|
RU2670272C2 |
| NOVEL USING 2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2002 |
|
RU2297833C2 |
| USE OF MAVOGLURANT TO REDUCE ALCOHOL USE OR TO PREVENT RECURRENT ALCOHOL USE | 2018 |
|
RU2806869C2 |
| 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZIOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(PROPYNYL)-7H-PYRAZOLO-[4, 3-e]-[1, 2, 4]-TRIAZOLO-[1, 5-c]PYRIMIDINE-5-AMINE | 2006 |
|
RU2417997C2 |
| BUSPIRON COMBINATION FOR TREATMENT OF FAINTNESS | 2018 |
|
RU2682966C1 |
| USE OF MAVOGLURANT TO REDUCE COCAINE INTAKE OR TO PREVENT RECURRENT COCAINE INTAKE | 2018 |
|
RU2804834C2 |
| COMBINATION OF ACETYLLEICINE FOR TREATMENT OF DIZZINESS | 2017 |
|
RU2680413C1 |
| GPR6 TETRAHYDROPYRIDOPYRAZINE MODULATORS | 2018 |
|
RU2818783C2 |
| NEW MODULATORS OF CORTICAL DOPAMINERGIC AND GLUTAMATERGIC NEUROTRANSMISSION MEDIATED BY NMDA-RECEPTOR | 2012 |
|
RU2593500C2 |
| TREATING PSYCHOLOGICAL CONDITIONS WITH USING M-MUSCARINIC ANTAGONISTS | 2007 |
|
RU2477634C2 |
